Dexcom Operating Cash Flow Growth & History (DXCM)
Dexcom's operating cash flow was $1.44B for fiscal 2025.
View full Dexcom company overviewDexcom annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.44B | $451.2M | +45.60% |
| 2024 | 2024-12-31 | $989.5M | $241.0M | +32.20% |
| 2023 | 2023-12-31 | $748.5M | $79.0M | +11.80% |
| 2022 | 2022-12-31 | $669.5M | $227.0M | +51.30% |
| 2021 | 2021-12-31 | $442.5M | −$33.1M | −6.96% |
| 2020 | 2020-12-31 | $475.6M | $161.1M | +51.22% |
| 2019 | 2019-12-31 | $314.5M | $191.3M | +155.28% |
| 2018 | 2018-12-31 | $123.2M | $31.2M | +33.91% |
| 2017 | 2017-12-31 | $92.0M | $35.8M | +63.70% |
| 2016 | 2016-12-31 | $56.2M | $7.2M | +14.69% |
| 2015 | 2015-12-31 | $49.0M | $25.4M | +107.63% |
| 2014 | 2014-12-31 | $23.6M | $21.2M | +883.33% |
| 2013 | 2013-12-31 | $2.4M | $35.5M | — |
| 2012 | 2012-12-31 | −$33.1M | −$3.0M | — |
| 2011 | 2011-12-31 | −$30.1M | $12.6M | — |
| 2010 | 2010-12-31 | −$42.7M | −$3.3M | — |
| 2009 | 2009-12-31 | −$39.4M | — | — |
Dexcom quarterly operating cash flow
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $269.2M | −$33.8M | −11.16% |
| Q1 2026 | 2026-03-31 | $525.6M | $341.8M | +185.96% |
| Q4 2025 | 2025-12-31 | $294.0M | −$7.4M | −2.46% |
| Q3 2025 | 2025-09-30 | $659.9M | $460.4M | +230.78% |
| Q2 2025 | 2025-06-30 | $303.0M | $23.6M | +8.45% |
| Q1 2025 | 2025-03-31 | $183.8M | −$25.4M | −12.14% |
| Q4 2024 | 2024-12-31 | $301.4M | $167.8M | +125.60% |
| Q3 2024 | 2024-09-30 | $199.5M | −$69.7M | −25.89% |
| Q2 2024 | 2024-06-30 | $279.4M | $89.1M | +46.82% |
| Q1 2024 | 2024-03-31 | $209.2M | $53.8M | +34.62% |
| Q4 2023 | 2023-12-31 | $133.6M | $1.1M | +0.83% |
| Q3 2023 | 2023-09-30 | $269.2M | −$24.0M | −8.19% |
| Q2 2023 | 2023-06-30 | $190.3M | $17.5M | +10.13% |
| Q1 2023 | 2023-03-31 | $155.4M | $84.4M | +118.87% |
| Q4 2022 | 2022-12-31 | $132.5M | $26.7M | +25.24% |
| Q3 2022 | 2022-09-30 | $293.2M | $45.9M | +18.56% |
| Q2 2022 | 2022-06-30 | $172.8M | $111.2M | +180.52% |
| Q1 2022 | 2022-03-31 | $71.0M | $43.2M | +155.40% |
| Q4 2021 | 2021-12-31 | $105.8M | −$66.2M | −38.49% |
| Q3 2021 | 2021-09-30 | $247.3M | $99.7M | +67.55% |
| Q2 2021 | 2021-06-30 | $61.6M | −$92.5M | −60.03% |
| Q1 2021 | 2021-03-31 | $27.8M | $25.9M | +1363.16% |
| Q4 2020 | 2020-12-31 | $172.0M | $28.3M | +19.69% |
| Q3 2020 | 2020-09-30 | $147.6M | $53.1M | +56.19% |
| Q2 2020 | 2020-06-30 | $154.1M | $89.6M | +138.91% |
| Q1 2020 | 2020-03-31 | $1.9M | −$9.9M | −83.90% |
| Q4 2019 | 2019-12-31 | $143.7M | $110.0M | +326.41% |
| Q3 2019 | 2019-09-30 | $94.5M | $37.7M | +66.37% |
| Q2 2019 | 2019-06-30 | $64.5M | $23.1M | +55.80% |
| Q1 2019 | 2019-03-31 | $11.8M | $20.5M | — |
| Q4 2018 | 2018-12-31 | $33.7M | −$7.5M | −18.20% |
| Q3 2018 | 2018-09-30 | $56.8M | $20.6M | +56.91% |
| Q2 2018 | 2018-06-30 | $41.4M | $27.1M | +189.51% |
| Q1 2018 | 2018-03-31 | −$8.7M | −$9.0M | — |
| Q4 2017 | 2017-12-31 | $41.2M | $27.9M | +209.77% |
| Q3 2017 | 2017-09-30 | $36.2M | $13.2M | +57.39% |
| Q2 2017 | 2017-06-30 | $14.3M | −$5.8M | −28.86% |
| Q1 2017 | 2017-03-31 | $300,000 | $500,000 | — |
| Q4 2016 | 2016-12-31 | $13.3M | $2.0M | +17.70% |
| Q3 2016 | 2016-09-30 | $23.0M | $5.1M | +28.49% |
| Q2 2016 | 2016-06-30 | $20.1M | $3.7M | +22.56% |
| Q1 2016 | 2016-03-31 | −$200,000 | −$3.6M | — |
| Q4 2015 | 2015-12-31 | $11.3M | $2.9M | +34.52% |
| Q3 2015 | 2015-09-30 | $17.9M | $6.5M | +57.02% |
| Q2 2015 | 2015-06-30 | $16.4M | $10.2M | +164.52% |
| Q1 2015 | 2015-03-31 | $3.4M | $5.8M | — |
| Q4 2014 | 2014-12-31 | $8.4M | $4.0M | +90.91% |
| Q3 2014 | 2014-09-30 | $11.4M | $9.8M | +612.50% |
| Q2 2014 | 2014-06-30 | $6.2M | $5.3M | +588.89% |
| Q1 2014 | 2014-03-31 | −$2.4M | $2.1M | — |
| Q4 2013 | 2013-12-31 | $4.4M | $15.0M | — |
| Q3 2013 | 2013-09-30 | $1.6M | $7.6M | — |
| Q2 2013 | 2013-06-30 | $900,000 | $7.2M | — |
| Q1 2013 | 2013-03-31 | −$4.5M | $5.7M | — |
| Q4 2012 | 2012-12-31 | −$10.6M | $944,000 | — |
| Q3 2012 | 2012-09-30 | −$6.0M | $741,000 | — |
| Q2 2012 | 2012-06-30 | −$6.3M | −$3.8M | — |
| Q1 2012 | 2012-03-31 | −$10.2M | −$911,000 | — |
| Q4 2011 | 2011-12-31 | −$11.5M | — | — |
| Q3 2011 | 2011-09-30 | −$6.7M | $2.7M | — |
| Q2 2011 | 2011-06-30 | −$2.5M | — | — |
| Q1 2011 | 2011-03-31 | −$9.3M | — | — |
| Q3 2010 | 2010-09-30 | −$9.5M | — | — |
Dexcom operating cash flow trends
Over the last five fiscal years, Dexcom's operating cash flow increased from $475.6M to $1.44B, a change of $965.1M. The latest reported quarter, Q2 2026, shows $269.2M.
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dexcom source filings ↗Community posts
Dexcom raises revenue and margin targets and authorizes a $1 billion buyback
Dexcom ($DXCM) lifted its 2026 sales forecast to $5.20–$5.25 billion, raising the midpoint, and increased its adjusted operating-margin target to approximately 24%. Third-quarter 2026 revenue increased 11% to $1.34 billion, with US growth o ...